Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry

Saved in:
Bibliographic Details
Published inAnnals of the rheumatic diseases Vol. 80; no. 1; pp. 134 - 136
Main Authors Winthrop, Kevin L, Citera, Gustavo, Gold, David, Henrohn, Dan, Connell, Carol A, Shapiro, Andrea B, Shi, Harry, Onofrei, Alina M, Pappas, Dimitrios A, Schulze-Koops, Hendrik
Format Journal Article
LanguageEnglish
Published England BMJ Publishing Group Ltd and European League Against Rheumatism 01.01.2021
Elsevier Limited
BMJ Publishing Group
Subjects
adalimumab
Adalimumab - therapeutic use
Age
Age Factors
Age groups
Aged
antirheumatic agents
Antirheumatic Agents - therapeutic use
arthritis
Arthritis, Rheumatoid - drug therapy
Biological Products - therapeutic use
biological therapy
Cardiovascular diseases
Clinical trials
Consent
Data dictionaries
Datasets
Etanercept
Female
Humans
Incidence
Infections
Infections - epidemiology
Information sharing
Janus Kinase Inhibitors - therapeutic use
Letter
Male
Medical equipment
Middle Aged
Monoclonal antibodies
Patients
Piperidines - therapeutic use
Proportional Hazards Models
Pyrimidines - therapeutic use
Registries
rheumatoid
Rheumatoid arthritis
Risk Factors
Safety
Tumor necrosis factor
tumor necrosis factor inhibitors
Tumors
United States - epidemiology
United States
New York
United States > US
arthritis
tumor necrosis factor inhibitors
antirheumatic agents
biological therapy
adalimumab
rheumatoid
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Correspondence-2
content type line 14
ObjectType-Letter to the Editor-1
ObjectType-Article-2
ObjectType-Correspondence-1
content type line 23
ISSN:0003-4967
1468-2060
1468-2060
DOI:10.1136/annrheumdis-2020-218992